NCT06911502

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) Vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 400 (estimated)
• Sponsor: Celgene · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymphoma who have received at least one line of prior systemic therapy.

Conditions

• Follicular Lymphoma

Interventions

Type	Name	Description
DRUG	Golcadomide	Specified dose on specified days
DRUG	Rituximab	Specified dose on specified days
DRUG	Lenalidomide	Specified dose on specified days
DRUG	Cyclophosphamide	Specified dose on specified days
DRUG	Doxorubicin	Specified dose on specified days
DRUG	Vincristine	Specified dose on specified days
DRUG	Prednisone/Prednisolone	Specified dose on specified days
DRUG	Bendamustine	Specified dose on specified days

Timeline

• Start date: 2025-07-28
• Primary completion: 2028-04-24
• Completion: 2030-07-31
• First posted: 2025-04-04
• Last updated: 2025-12-05

Locations

160 sites across 21 countries: United States, Australia, Brazil, Canada, Chile, China, Finland, France, Germany, Greece, India, Italy, Japan, Netherlands, Poland, Saudi Arabia, South Korea, Spain, Turkey (Türkiye), United Arab Emirates, United Kingdom

Regulatory

• FDA-regulated drug study